Compare IDEXX Laboratories, Inc. (IDXX) vs Macy's Inc (M) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Macy's Inc — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while Macy's Inc trades at $23.84 (market cap $6.45B). The key difference: IDEXX Laboratories, Inc. is far larger — about 7.2× Macy's Inc's market cap, and Macy's Inc pays a 3.12% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | M | |
|---|---|---|
Market Cap | $46.22B | $6.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $26.21 |
52-Week Low | $526.44 | $12.73 |
Enterprise Value | $47.12B | $10.26B |
Dividend Yield | — | 3.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Macy's (M) trades at $23.92, down 3.94% in the last session, with a bullish technical signal and recent earnings beats. The stock shows attractive valuation metrics including a P/E of 10.13 and P/S of 0.3, while maintaining positive cash flow generation. Recent institutional buying and analyst coverage indicate growing confidence in the company's turnaround strategy.
The outlook remains cautiously optimistic with a consensus price target of $24.83 offering 4% upside potential. Key risks include retail sector headwinds and competitive pressures, but strong institutional interest and improving fundamentals support the case for gradual recovery. The dividend payment scheduled for July provides additional shareholder return.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →
